June 2020 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2022 Concepts

Scaling up PrEP and STI Services To End HIV in the United States

For the published request for applications, see the June 15, 2021 Guide announcement, Innovative Models for Delivering PrEP and STI Services To Stop HIV in the United States (R61/R33, Clinical Trial Optional).

Detection of HIV for Self-Testing

For the published program announcement with special receipt, referral, and/or review considerations, see the November 13, 2020 Guide announcement; Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed).

Limited Interaction Targeted Epidemiology (LITE-2) To Advance HIV Prevention 

For the published request for applications, see the April 7, 2021 Guide announcement, Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3, Clinical Trial Optional).

Assessing Women at Risk: Epidemiology To End the HIV Epidemic (AWARE)

Request for Applications—proposed FY 2022 initiative

Contact: Joana Roe

Objective: Focused research efforts that provide meaningful, significant clues for identifying susceptible women and preventing HIV infection are needed. This initiative aims to support research that will combine epidemiologic methods, mobile technology, and data science to enroll women living in the United States and gather information that can influence public health strategies and ultimately decrease the incidence of HIV in women.

Description: This new initiative will solicit applications that propose using a combination of qualitative data collection, mobile technology, big data sources and analytic methods to: 1) identify at-risk women living in the United States and 2) assess the multifactorial processes and barriers that contribute to persistence of new cases of HIV infection in this key population.

The initiative will support this novel combination of approaches to understand HIV transmission and the care-cascade for women living in the United States. The proposed research should 1) identify women at high risk for HIV acquisition, 2) elucidate important and modifiable risk factors, and 3) promote testing for HIV and other sexually transmitted infections.

Modern data collection methods, such as digital cohorts and online surveys, are needed to assemble cohorts that are large enough to describe the epidemiology of HIV risk among women in the United States. Investigators may choose to also enroll cohorts of women who are recently infected for case-control study designs, which can be used to augment information obtained in larger digital cohorts of women at risk. Successful applicants must demonstrate:

  • Feasibility–experienced and successful in enrolling and retaining women
  • Ability to reach at-risk women, with culturally appropriate approaches
  • Formation of a multidisciplinary team, which must include epidemiologists, data scientists, and community members

Applications of interest include those that:

  • Identify gaps in behavioral, social patterns, and other determinants to improve HIV prevention specifically in women
  • Use heterogenous data sources to define the social, behavioral, and contextual life course events related to risk to women
  • Apply simulation and other types of modeling to explain patterns in social networks as well as risk and health-seeking behaviors, in space and time
  • Differentiate role of gender, race and ethnicity, sexual preference, geographic as well as economic factors to explain disparities in HIV acquisition, and access to and retention in care
  • Use viral phylogenetics to define HIV transmission networks for women, identify areas to influence, and disrupt transmission of HIV to them
  • Inform evidence-based projects that can influence and impact strategies for women

Centers for HIV Structural Biology

For the published request for applications, see the April 20, 2021 Guide announcement, Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed).

Understanding HIV Reservoir Dynamics

For the published request for applications, see the April 7, 2021 Guide announcement, Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed).

New Technologies for the In Vivo Delivery of Gene Therapeutics for an HIV Cure

For the published request for applications, see the October 20, 2020 Guide announcement, New Technologies for the In Vivo Delivery of Gene Therapeutics for an HIV Cure (R01, Clinical Trial Not Allowed).

Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA

For the published request for applications, see the March 31, 2021 Guide announcement, Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33, Clinical Trial Not Allowed).

Understanding and Overcoming Resistance to Broadly Neutralizing Antibodies (bNAbs) Targeting HIV

For the published request for applications, see the March 30, 2021 Guide announcement, Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01, Clinical Trial Not Allowed).

HIV Vaccine Research and Design (HIVRAD) Program

For the published program announcement with special receipt, referral, and/or review considerations, see the September 3, 2020 Guide announcement, HIV Vaccine Research and Design (HIVRAD) Program (P01, Clinical Trial Not Allowed).

 

Content last reviewed on